BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-1845. [PMID: 8196726 DOI: 10.1056/nejm199406303302601] [Cited by in Crossref: 1147] [Cited by in F6Publishing: 1066] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Kakkadasam Ramaswamy P, Kumar S, Kedia S, McGregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis SPL, Satsangi J. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 2022:gutjnl-2022-327533. [PMID: 36171080 DOI: 10.1136/gutjnl-2022-327533] [Reference Citation Analysis]
2 Kawakami A, Tanaka M, Sakagami K, Choong LM, Kunisaki R, Maeda S, Bjarnason I, Ito H, Hayee B. Daily life difficulties among patients with ulcerative colitis in Japan and the United Kingdom: A comparative study. Medicine 2022;101:e30216. [DOI: 10.1097/md.0000000000030268] [Reference Citation Analysis]
3 Kumar S, Pollok R, Goldsmith D. Renal and Urological Disorders Associated With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac140. [PMID: 35942657 DOI: 10.1093/ibd/izac140] [Reference Citation Analysis]
4 Jordi SBU, Lang BM, Wyss J, Auschra B, Yilmaz B, Krupka N, Greuter T, Schreiner P, Biedermann L, Preisig M, von Känel R, Rogler G, Begré S, Misselwitz B; Swiss IBD cohort study group. The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients. J Gastroenterol 2022. [PMID: 35900592 DOI: 10.1007/s00535-022-01902-7] [Reference Citation Analysis]
5 Lopes MB, Lyra AC, Rocha R, Coqueiro FG, Lima CA, de Oliveira CC, Santana GO. Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis. World J Gastrointest Pharmacol Ther 2022; 13(4): 57-66 [DOI: 10.4292/wjgpt.v13.i4.57] [Reference Citation Analysis]
6 Renaud M, Ayav A, Caron B, Peyrin-biroulet L, Germain A. Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis? JCM 2022;11:3857. [DOI: 10.3390/jcm11133857] [Reference Citation Analysis]
7 Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT, Johnson D, Ng SC, Sharma V, Rubin DT, Gibson PR, Christensen B. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther 2022;56:6-27. [PMID: 35596242 DOI: 10.1111/apt.16952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Uchiyama K, Takagi T, Mizushima K, Asaeda K, Kajiwara M, Kashiwagi S, Minagawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Kishimoto M, Naito Y, Itoh Y. Investigation on the Inhibitory Effect of Wnt-5a on Colonic Mucosal Inflammation in Patients with Ulcerative Colitis. Dig Dis Sci 2022. [PMID: 35590045 DOI: 10.1007/s10620-022-07537-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kitae H, Takagi T, Naito Y, Inoue R, Azuma Y, Torii T, Mizushima K, Doi T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, Ishikawa T, Konishi H, Itoh Y. Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis. Microorganisms 2022;10:1044. [DOI: 10.3390/microorganisms10051044] [Reference Citation Analysis]
10 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
11 Markovic M, Ben-shabat S, Nagendra Manda J, Abramov-harpaz K, Regev C, Miller Y, Aponick A, Zimmermann EM, Dahan A. PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy. Pharmaceutics 2022;14:675. [DOI: 10.3390/pharmaceutics14030675] [Reference Citation Analysis]
12 Falah F, Vasiee A, Ramezani M, Tabatabaee-yazdi F, Mortazavi SA, Danesh A. Effect of immobilization, mutation, and microbial stresses on increasing production efficiency of “Cyclosporin A”. Biomass Conv Bioref . [DOI: 10.1007/s13399-022-02533-x] [Reference Citation Analysis]
13 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
14 Markovic M, Abramov-Harpaz K, Regev C, Ben-Shabat S, Aponick A, Zimmermann EM, Miller Y, Dahan A. Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospholipid-Linker-Cyclosporine PLA2-Mediated Activation. Int J Mol Sci 2022;23:2673. [PMID: 35269813 DOI: 10.3390/ijms23052673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tarabar D, El Jurdi K, Traboulsi C, Yvellez O, Milenkovic Z, Petrovic S, Subotic B, Gils A, Brocic T, Brcerevic I, Latinovic O, Jocic T, Rubin DT. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab328] [Reference Citation Analysis]
16 Unal U, Comertpay B, Demirtas TY, Gov E. Drug repurposing for rheumatoid arthritis: Identification of new drug candidates via bioinformatics and text mining analysis. Autoimmunity 2022;:1-10. [PMID: 35048767 DOI: 10.1080/08916934.2022.2027922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fleshner P, Melmed GY. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. Clin Colon Rectal Surg 2022;35:066-71. [DOI: 10.1055/s-0041-1740030] [Reference Citation Analysis]
18 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
19 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Minagawa Y, Uchiyama K, Takagi T, Mizushima K, Asaeda K, Kajiwara-kubota M, Kashiwagi S, Hotta Y, Tanaka M, Inoue K, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Naito Y, Itoh Y. Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.22-33] [Reference Citation Analysis]
21 Yamada K, Ishikawa T, Kawashima H, Ohno E, Iida T, Ishikawa E, Mizutani Y, Sawada T, Maeda K, Yamamura T, Kakushima N, Furukawa K, Nakamura M, Ishigami M, Fujishiro M. Evaluation of ulcerative colitis activity using transabdominal ultrasound shear wave elastography. Quant Imaging Med Surg 2022;12:618-26. [PMID: 34993106 DOI: 10.21037/qims-21-403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol 2021;21:494. [PMID: 34949172 DOI: 10.1186/s12876-021-02043-6] [Reference Citation Analysis]
24 Venkateswaran N, Weismiller S, Clarke K. Indeterminate Colitis - Update on Treatment Options. J Inflamm Res 2021;14:6383-95. [PMID: 34876831 DOI: 10.2147/JIR.S268262] [Reference Citation Analysis]
25 Forbes A. Immunosuppressants and immune modulators in luminal gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101759. [PMID: 34874843 DOI: 10.1016/j.bpg.2021.101759] [Reference Citation Analysis]
26 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
27 Peters V, Dijkstra G, Campmans-Kuijpers MJE. Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2021:nuab062. [PMID: 34486663 DOI: 10.1093/nutrit/nuab062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Kantidakis JD, Moulding R, Knowles SR. Psychological mediators of psychological distress and quality of life in inflammatory bowel disease. J Psychosom Res 2021;149:110596. [PMID: 34418720 DOI: 10.1016/j.jpsychores.2021.110596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep 2021;11:16440. [PMID: 34385588 DOI: 10.1038/s41598-021-96019-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Liu C, Mo LH, Feng BS, Jin QR, Li Y, Lin J, Shu Q, Liu ZG, Liu Z, Sun X, Yang PC. Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. Theranostics 2021;11:7797-812. [PMID: 34335965 DOI: 10.7150/thno.62256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Shaffer SR, Traboulsi C, Krugliak Cleveland N, Rubin DT. Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis. ACG Case Rep J 2021;8:e00604. [PMID: 34007860 DOI: 10.14309/crj.0000000000000604] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tanaka M, Takagi T, Naito Y, Uchiyama K, Hotta Y, Toyokawa Y, Kashiwagi S, Kamada K, Ishikawa T, Yasuda H, Konishi H, Itoh Y. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open 2021;5:377-81. [PMID: 33732885 DOI: 10.1002/jgh3.12506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Shimozaki K, Hirata K, Horie S, Chida A, Tsugaru K, Hayashi Y, Kawasaki K, Miyanaga R, Hayashi H, Mizuno R, Funakoshi T, Hosoe N, Hamamoto Y, Kanai T. The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. Diagnostics (Basel) 2021;11:543. [PMID: 33803735 DOI: 10.3390/diagnostics11030543] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Uchiyama K, Takagi T, Mizushima K, Kajiwara-Kubota M, Kashiwagi S, Toyokawa Y, Tanaka M, Hotta Y, Kamada K, Ishikawa T, Konishi H, Kishimoto M, Naito Y, Itoh Y. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. BMC Gastroenterol 2021;21:122. [PMID: 33730998 DOI: 10.1186/s12876-021-01709-5] [Reference Citation Analysis]
38 Nakov R, Nakov V. Young age and short duration of the disease are associated with more frequent relapses in inflammatory bowel disease patients. Med Pharm Rep 2021;94:43-7. [PMID: 33629047 DOI: 10.15386/mpr-1510] [Reference Citation Analysis]
39 Tanaka M, Nakanishi M, Miyazaki H, Morita R, Eguchi H, Takeda Y, Katayama M, Tanaka M, Bamba M, Shigematsu T. Granulocyte and Monocyte Adsorptive Apheresis for Ulcerative Colitis in a Patient with Low Bone Mineral Density Due to Fanconi-Bickel Syndrome. Intern Med 2021;60:2413-7. [PMID: 33612684 DOI: 10.2169/internalmedicine.6707-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS One 2021;16:e0246871. [PMID: 33571293 DOI: 10.1371/journal.pone.0246871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Philippou A, Rizvi A, Steinlauf A. Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine. Case Rep Gastroenterol 2021;15:147-53. [PMID: 33708063 DOI: 10.1159/000512426] [Reference Citation Analysis]
43 Ghoshal UC, Sahu S, Biswas SN, Singh P, Chaudhary M, Ghoshal U, Tiwari P, Rai S, Mishra SK. Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology. JGH Open 2021. [PMID: 33821221 DOI: 10.1002/jgh3.12498] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
44 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
46 Murasugi S, Ito A, Omori T, Nakamura S, Tokushige K. Clinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis. Gastroenterol Res Pract 2020;2020:7969628. [PMID: 33224192 DOI: 10.1155/2020/7969628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
48 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
49 Moein S, Vaghari-Tabari M, Qujeq D, Kashifard M, Shokri-Shirvani J, Hajian-Tilaki K. Association between serum folate with inflammatory markers, disease clinical activity and serum homocysteine in patients with inflammatory bowel disease. Does folate level have an effect on maintaining clinical remission? Acta Biomed 2020;91:e2020106. [PMID: 33525287 DOI: 10.23750/abm.v91i4.8467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Jia X, Guo R, Hu Z, Liu J, Liu J, Li B, Yang Q, He J. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis. Medicine (Baltimore) 2020;99:e22894. [PMID: 33126341 DOI: 10.1097/MD.0000000000022894] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Ganzleben I, Geppert C, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, Rath T, Nagore D, Neurath MF, Atreya R. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112. [PMID: 33101457 DOI: 10.1177/1756284820954112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
52 Kato T, Iwasaki T, Arihiro S, Saruta M. Endoscopic visualization of cancer and dysplasia in patients with ulcerative colitis following sensitization with oral 5-aminolevulinic acid. J Dig Dis 2020;21:498-504. [PMID: 32686910 DOI: 10.1111/1751-2980.12923] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Kobayashi N, Arihiro S, Shimada K, Hoshino A, Saijo H, Oka N, Saruta M, Kondo K. Activating transcription factor 3 (ATF3) as a perspective biomarker of Crohn’s disease. Eur J Inflamm 2020;18:205873922092979. [DOI: 10.1177/2058739220929790] [Reference Citation Analysis]
54 Rosen MH, Axelrad J, Hudesman D, Rubin DT, Chang S. Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. Inflamm Bowel Dis 2020;26:971-3. [PMID: 32393973 DOI: 10.1093/ibd/izaa109] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
55 Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Desai J, Elnaggar M, Hanfy AA, Doshi R. Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions. Clin Exp Gastroenterol 2020;13:203-10. [PMID: 32547151 DOI: 10.2147/CEG.S200760] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
58 Peter I, Maldonado-Contreras A, Eisele C, Frisard C, Simpson S, Nair N, Rendon A, Hawkins K, Cawley C, Debebe A, Tarassishin L, White S, Dubinsky M, Stone J, Clemente JC, Sabino J, Torres J, Hu J, Colombel JF, Olendzki B. A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design. Contemp Clin Trials Commun 2020;18:100573. [PMID: 32617430 DOI: 10.1016/j.conctc.2020.100573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 Marcil V, Levy E, Amre D, Bitton A, Sant'Anna AMGA, Szilagy A, Sinnett D, Seidman EG. A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping? Inflamm Bowel Dis 2019;25:1428-41. [PMID: 30793155 DOI: 10.1093/ibd/izy403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
60 Fukuda T, Naganuma M, Takabayashi K, Hagihara Y, Tanemoto S, Nomura E, Yoshimatsu Y, Sugimoto S, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Mutaguchi M, Inoue N, Ogata H, Iwao Y, Abe T, Kanai T. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. J Gastroenterol Hepatol 2020;35:1878-85. [PMID: 32250471 DOI: 10.1111/jgh.15059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
61 Ghoshal UC, Rai S, Kulkarni A, Gupta A. Prediction of outcome of treatment of acute severe ulcerative colitis using principal component analysis and artificial intelligence. JGH Open. 2020;4:889-897. [PMID: 33102760 DOI: 10.1002/jgh3.12342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
62 Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. J Crohns Colitis. 2018;. [PMID: 29762697 DOI: 10.1093/ecco-jcc/jjy064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
63 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Fournier A, Mondillon L, Luminet O, Canini F, Mathieu N, Gauchez AS, Dantzer C, Bonaz B, Pellissier S. Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome. Front Psychiatry 2020;11:229. [PMID: 32300314 DOI: 10.3389/fpsyt.2020.00229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
65 Arihiro S, Nakashima A, Matsuoka M, Suto S, Uchiyama K, Kato T, Mitobe J, Komoike N, Itagaki M, Miyakawa Y, Koido S, Hokari A, Saruta M, Tajiri H, Matsuura T, Urashima M. Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1088-95. [PMID: 30601999 DOI: 10.1093/ibd/izy346] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 23.0] [Reference Citation Analysis]
66 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
67 Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol 2020;24:397-419. [PMID: 32124113 DOI: 10.1007/s10151-020-02175-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
68 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
69 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
70 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
71 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
72 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 122] [Article Influence: 33.5] [Reference Citation Analysis]
73 Fan X, Ding X, Zhang QY. Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model. Acta Pharm Sin B 2020;10:123-35. [PMID: 31993311 DOI: 10.1016/j.apsb.2019.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
74 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
75 Shibuya T, Nomura K, Okahara K, Haga K, Nomura O, Murakami T, Uchida S, Kodani T, Ishikawa D, Sakamoto N, Ogihara T, Osada T, Nagahara A. Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy. Med Sci Monit 2019;25:9855-63. [PMID: 31865359 DOI: 10.12659/MSM.918562] [Reference Citation Analysis]
76 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
77 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
78 Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K, Kato J, Okada H. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. J Clin Med 2019;8:E2109. [PMID: 31810227 DOI: 10.3390/jcm8122109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 555] [Article Influence: 205.7] [Reference Citation Analysis]
80 Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020;4:561-4. [PMID: 32782938 DOI: 10.1002/jgh3.12280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
81 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
82 Weissman S, Chris-Olaiya A, Mehta TI, Aziz M, Alshati A, Berry R, Fatima R, Kolli S, Hassan A, Sciarra MA. A novel player: cyclosporine therapy in the management of inflammatory bowel disease. Transl Gastroenterol Hepatol 2019;4:67. [PMID: 31620649 DOI: 10.21037/tgh.2019.08.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wang X, Wang G, Shang J, Pan H, Zhang XA, Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res 2019;47:3534-49. [PMID: 31364448 DOI: 10.1177/0300060519864800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. Revista de Gastroenterología de México (English Edition) 2019;84:317-25. [DOI: 10.1016/j.rgmxen.2019.02.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis 2018;24:1291-7. [PMID: 29506124 DOI: 10.1093/ibd/izx105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
86 Yanagisawa K, Murakami M, Kondo Y, Oguma S, Kobayashi S, Miyasaka H, Shinohara T, Tomori A, Nakano Y, Furuhata S, Ikezoe M. Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients With Ulcerative Colitis. Ther Apher Dial 2019;23:217-23. [PMID: 31025815 DOI: 10.1111/1744-9987.12818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Bernstein CN, Kornbluth A. Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. Am J Gastroenterol 2017;112:1719-21. [PMID: 29109492 DOI: 10.1038/ajg.2017.282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
89 Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 2019; 25(13): 1603-1617 [PMID: 30983820 DOI: 10.3748/wjg.v25.i13.1603] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
90 Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. Dig Dis Sci 2019;64:2265-72. [PMID: 30796684 DOI: 10.1007/s10620-019-05520-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
91 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
92 Spagnoli C, Pisani F, Di Mario F, Leandro G, Gaiani F, De' Angelis GL, Fusco C. Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association. Acta Biomed 2018;89:22-32. [PMID: 30561392 DOI: 10.23750/abm.v89i9-S.7956] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
93 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
94 Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther 2018;35:1746-62. [PMID: 30374806 DOI: 10.1007/s12325-018-0795-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
95 Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res 2018;16:609-18. [PMID: 30301329 DOI: 10.5217/ir.2018.00044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
97 Okabayashi S, Kobayashi T, Hibi T. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflamm Intest Dis 2018;3:25-31. [PMID: 30505839 DOI: 10.1159/000491878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
98 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
99 Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
100 Vedamurthy A, Xu L, Luther J, Colizzo F, Garber JJ, Khalili H, Ananthakrishnan AN. Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. Dig Dis Sci 2018;63:2740-6. [PMID: 29951797 DOI: 10.1007/s10620-018-5176-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
101 Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2019;17:486-93. [PMID: 29751166 DOI: 10.1016/j.cgh.2018.04.060] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
102 Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 31.8] [Reference Citation Analysis]
103 Ribiere S, Leconte M, Chaussade S, Abitbol V. [Acute severe colitis]. Presse Med 2018;47:312-9. [PMID: 29618409 DOI: 10.1016/j.lpm.2018.02.020] [Reference Citation Analysis]
104 Naeem M, Bae J, Oshi MA, Kim MS, Moon HR, Lee BL, Im E, Jung Y, Yoo JW. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine 2018;13:1225-40. [PMID: 29535519 DOI: 10.2147/IJN.S157566] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
105 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Lambert J, Mary JY, Louis E; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237-43. [PMID: 28053054 DOI: 10.1136/gutjnl-2016-313060] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 21.8] [Reference Citation Analysis]
106 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
107 Lima CA, Lyra AC, Mendes CMC, Lopes MB, Coqueiro FG, Rocha R, Santana GO. Bone mineral density and inflammatory bowel disease severity. Braz J Med Biol Res 2017;50:e6374. [PMID: 29069227 DOI: 10.1590/1414-431X20176374] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
108 Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy: A Retrospective Evaluation. Intern Med 2018;57:159-64. [PMID: 29033411 DOI: 10.2169/internalmedicine.8550-16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
109 Moreau B, Clement P, Theoret Y, Seidman EG. Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD. Therap Adv Gastroenterol 2017;10:819-27. [PMID: 29147133 DOI: 10.1177/1756283X17733657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
110 Matsumoto S, Kawamura H, Nishikawa T, Sagihara N, Miyatani H, Mashima H. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol 2017;10:249-58. [PMID: 29026326 DOI: 10.2147/CEG.S143224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
111 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Intern Med. 2017;56:2705-2710. [PMID: 28924114 DOI: 10.2169/internalmedicine.8428-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
112 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
113 Leeds IL, Truta B, Parian AM, Chen SY, Efron JE, Gearhart SL, Safar B, Fang SH. Early Surgical Intervention for Acute Ulcerative Colitis Is Associated with Improved Postoperative Outcomes. J Gastrointest Surg. 2017;21:1675-1682. [PMID: 28819916 DOI: 10.1007/s11605-017-3538-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
114 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
115 Kobayashi T, Matsuoka K, Yokoyama Y, Nakamura T, Ino T, Numata T, Shibata H, Aoki H, Matsuno Y, Hibi T. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. J Gastroenterol 2018;53:387-96. [PMID: 28597225 DOI: 10.1007/s00535-017-1356-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
116 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
117 Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017; 8(2): 114-119 [PMID: 28533920 DOI: 10.4292/wjgpt.v8.i2.114] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
118 Vogelaar L, de Haar C, Aerts BR, Peppelenbosch MP, Timman R, Hanssen BE, van der Woude CJ. Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters. Clin Exp Gastroenterol. 2017;10:83-90. [PMID: 28496351 DOI: 10.2147/ceg.s123942] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
119 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
120 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
121 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 1116] [Article Influence: 138.3] [Reference Citation Analysis]
122 Rieder F, Kurada S, Grove D, Cikach F, Lopez R, Patel N, Singh A, Alkhouri N, Shen B, Brzezinski A, Baker M, Fiocchi C, Dweik RA. A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications. Clin Transl Gastroenterol 2016;7:e201. [PMID: 27831543 DOI: 10.1038/ctg.2016.57] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
123 Komine-Aizawa S, Masuda H, Mazaki T, Shiono M, Hayakawa S, Takayama T. Plasma osteopontin predicts inflammatory bowel disease activities. Int Surg 2015;100:38-43. [PMID: 25594638 DOI: 10.9738/INTSURG-D-13-00160.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
124 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
125 Alonso A, Julià A, Vinaixa M, Domènech E, Fernández-Nebro A, Cañete JD, Ferrándiz C, Tornero J, Gisbert JP, Nos P, Casbas AG, Puig L, González-Álvaro I, Pinto-Tasende JA, Blanco R, Rodríguez MA, Beltran A, Correig X, Marsal S; IMID Consortium. Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Med 2016;14:133. [PMID: 27609333 DOI: 10.1186/s12916-016-0681-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
126 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 11.2] [Reference Citation Analysis]
127 Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol 2016;3:e000103. [PMID: 27648296 DOI: 10.1136/bmjgast-2016-000103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
128 Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study. Gastroenterol Res Pract 2016;2016:5956316. [PMID: 27413367 DOI: 10.1155/2016/5956316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
129 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
130 Santocchi E, Guiducci L, Fulceri F, Billeci L, Buzzigoli E, Apicella F, Calderoni S, Grossi E, Morales MA, Muratori F. Gut to brain interaction in Autism Spectrum Disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters. BMC Psychiatry 2016;16:183. [PMID: 27260271 DOI: 10.1186/s12888-016-0887-5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 77] [Article Influence: 16.2] [Reference Citation Analysis]
131 Laharie D, Poullenot F. Letter: which patient profile for tacrolimus in ulcerative colitis? Aliment Pharmacol Ther 2016;43:1242-3. [PMID: 27137730 DOI: 10.1111/apt.13598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A. Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med. 2016;12:829-834. [PMID: 27446283 DOI: 10.3892/etm.2016.3341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
133 Sugimoto S, Naganuma M, Kanai T. Indole compounds may be promising medicines for ulcerative colitis. J Gastroenterol 2016;51:853-61. [DOI: 10.1007/s00535-016-1220-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 10.3] [Reference Citation Analysis]
134 McLean LP, Cross RK. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol 2016;12:833-42. [PMID: 27096357 DOI: 10.1080/17425255.2016.1181171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Feuerstein JD, Akbari M, Tapper EB, Cheifetz AS. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol 2016;29:341-7. [PMID: 27366036 DOI: 10.20524/aog.2016.0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
136 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
137 Safroneeva E, Vavricka SR, Fournier N, Straumann A, Rogler G, Schoepfer AM. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2015;21:1348-1358. [PMID: 25806845 DOI: 10.1097/mib.0000000000000368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
138 Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 15.0] [Reference Citation Analysis]
139 Kato J, Hiraoka S, Nakarai A, Takashima S, Inokuchi T, Ichinose M. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016;14:5-14. [PMID: 26884729 DOI: 10.5217/ir.2016.14.1.5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
140 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
141 Heal JW, Wells SA, Blindauer CA, Freedman RB, Römer RA. Characterization of folding cores in the cyclophilin A-cyclosporin A complex. Biophys J 2015;108:1739-46. [PMID: 25863065 DOI: 10.1016/j.bpj.2015.02.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
142 Kumar M, Hemalatha R, Nagpal R, Singh B, Parasannanavar D, Verma V, Kumar A, Marotta F, Catanzaro R, Cuffari B, Jain S, Bissi L, Yadav H. PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE. Int J Probiotics Prebiotics 2016;11:99-116. [PMID: 31452650] [Reference Citation Analysis]
143 Dogan S, Guven K, Celikbilek M, Deniz K, Saraymen B, Gursoy S. Serum Visfatin Levels in Ulcerative Colitis. J Clin Lab Anal 2016;30:552-6. [PMID: 26668098 DOI: 10.1002/jcla.21901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
144 Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2016;10:484-494. [PMID: 26645641 DOI: 10.1093/ecco-jcc/jjv221] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
145 Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015; 7(27): 2716-2728 [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
146 Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol 2015; 21(44): 12519-12543 [PMID: 26640330 DOI: 10.3748/wjg.v21.i44.12519] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
147 Tabatabaeian M, Afshar H, Roohafza HR, Daghaghzadeh H, Feizi A, Sharbafchi MR, Tabatabaeian M, Naji F, Adibi P. Psychological status in Iranian patients with ulcerative colitis and its relation to disease activity and quality of life. J Res Med Sci 2015;20:577-84. [PMID: 26600833 DOI: 10.4103/1735-1995.165962] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
148 Daghaghzadeh H, Naji F, Afshar H, Sharbafchi MR, Feizi A, Maroufi M, Tabatabaeeyan M, Adibi P, Tavakoli H. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study. J Res Med Sci 2015;20:595-601. [PMID: 26600836 DOI: 10.4103/1735-1995.165969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
149 Macken L, Blaker PA. Management of acute severe ulcerative colitis (NICE CG 166). Clin Med (Lond) 2015;15:473-6. [PMID: 26430189 DOI: 10.7861/clinmedicine.15-5-473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
150 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
151 Selvaggi F, Pellino G, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Tech Coloproctol 2015;19:627-38. [PMID: 26386867 DOI: 10.1007/s10151-015-1367-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
152 Matsumoto S, Yoshida Y. Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study. Clin Exp Gastroenterol 2015;8:225-30. [PMID: 26347309 DOI: 10.2147/CEG.S86528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
154 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
155 Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51:241-251. [PMID: 26162647 DOI: 10.1007/s00535-015-1102-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 10.1] [Reference Citation Analysis]
156 Yamada S, Yoshino T, Matsuura M, Kimura M, Koshikawa Y, Minami N, Toyonaga T, Honzawa Y, Nakase H. Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res 2015;13:250-8. [PMID: 26131000 DOI: 10.5217/ir.2015.13.3.250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
157 Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015;13:219-226. [PMID: 26130996 DOI: 10.5217/ir.2015.13.3.219] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
158 Hiraoka S, Kato J, Moritou Y, Takei D, Inokuchi T, Nakarai A, Takahashi S, Harada K, Okada H, Yamamoto K. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. BMC Gastroenterol. 2015;15:53. [PMID: 25925267 DOI: 10.1186/s12876-015-0285-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
159 Guilfoyle SM, Gray WN, Herzer-Maddux M, Hommel KA. Parenting stress predicts depressive symptoms in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2014;26:964-71. [PMID: 25003746 DOI: 10.1097/MEG.0000000000000149] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
160 Takaoka A, Sasaki M, Kurihara M, Iwakawa H, Inoue M, Bamba S, Ban H, Andoh A, Miyazaki Y. Comparison of energy metabolism and nutritional status of hospitalized patients with Crohn's disease and those with ulcerative colitis. J Clin Biochem Nutr 2015;56:208-14. [PMID: 26060351 DOI: 10.3164/jcbn.14-95] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
161 Faria RJ, Clemente CM, Carneiro FP, Santos-Neto L. Can IgG4 Levels Identify the Ulcerative Colitis Subtype of Inflammatory Bowel Disease? Gastroenterology Res 2015;8:178-85. [PMID: 27785293 DOI: 10.14740/gr648w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
162 Inoue M, Sasaki M, Takaoka A, Kurihara M, Iwakawa H, Bamba S, Ban H, Andoh A. Changes in energy metabolism after induction therapy in patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr 2015;56:215-9. [PMID: 26060352 DOI: 10.3164/jcbn.14-100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
163 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
164 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
165 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
166 Çekiç C, İpek S, Aslan F, Akpınar Z, Arabul M, Topal F, Sarıtaş Yüksel E, Alper E, Ünsal B. The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency. Gastroenterol Res Pract 2015;2015:582163. [PMID: 25691898 DOI: 10.1155/2015/582163] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
167 Keller JJ, Wang J, Hwang YL, Chou CC, Wang LH, Hsu JL, Bai CH, Chiou HY. Increased risk of stroke among patients with Crohn's disease: a population-based matched cohort study. Int J Colorectal Dis 2015;30:645-53. [PMID: 25608496 DOI: 10.1007/s00384-015-2132-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
168 Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Maeda K, Morise K, Matsushita M, Furukawa K, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. World J Gastroenterol 2015; 21(1): 254-261 [PMID: 25574099 DOI: 10.3748/wjg.v21.i1.254] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
169 Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114-126. [PMID: 25488896 DOI: 10.1038/ajg.2014.357] [Cited by in Crossref: 111] [Cited by in F6Publishing: 119] [Article Influence: 13.9] [Reference Citation Analysis]
170 Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473-487. [PMID: 25525379 DOI: 10.2147/ceg.s27530] [Cited by in Crossref: 57] [Cited by in F6Publishing: 116] [Article Influence: 7.1] [Reference Citation Analysis]
171 Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(4): 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
172 Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2014;20:14-20. [PMID: 24297054 DOI: 10.1097/01.MIB.0000437497.07181.05] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
173 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
174 Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
175 Schuman SL, Graef DM, Janicke DM, Gray WN, Hommel KA. An exploration of family problem-solving and affective involvement as moderators between disease severity and depressive symptoms in adolescents with inflammatory bowel disease. J Clin Psychol Med Settings 2013;20:488-96. [PMID: 23793840 DOI: 10.1007/s10880-013-9368-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
176 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
177 Veit LE, Maranda L, Fong J, Nwosu BU. The vitamin D status in inflammatory bowel disease. PLoS One 2014;9:e101583. [PMID: 24992465 DOI: 10.1371/journal.pone.0101583] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
178 Nagayama K, Takedatsu H, Mitsuyama K, Yamasaki H, Kuwaki K, Yoshioka S, Kobayashi T, Yamauchi R, Kakuma T, Sata M. Univariate analysis to examine predictors of response to leukocytapheresis in ulcerative colitis patients. Ther Apher Dial 2014;18:244-51. [PMID: 24965290 DOI: 10.1111/1744-9987.12211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
179 Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 2014;6:37-42. [PMID: 25002818 DOI: 10.4137/OED.S16067] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
180 Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One 2014;9:e99293. [PMID: 24932476 DOI: 10.1371/journal.pone.0099293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
181 Vogelaar L, van't Spijker A, Timman R, van Tilburg AJ, Bac D, Vogelaar T, Kuipers EJ, van Busschbach JJ, van der Woude CJ. Fatigue management in patients with IBD: a randomised controlled trial. Gut 2014;63:911-8. [PMID: 23884638 DOI: 10.1136/gutjnl-2013-305191] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
182 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
183 Chapman CG, Bochenek A, Stein AC, Rubin DT. Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis. ACG Case Rep J 2014;1:148-50. [PMID: 26157857 DOI: 10.14309/crj.2014.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
184 Celikbilek A, Celikbilek M, Sabah S, Tanık N, Borekci E, Dogan S, Akin Y, Baldane S, Deniz K, Yilmaz N. The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis. Int J Inflam. 2014;2014:986525. [PMID: 24790767 DOI: 10.1155/2014/986525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
185 Fukuda K, Fujita Y. Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis. BMC Gastroenterol. 2014;14:49. [PMID: 24641276 DOI: 10.1186/1471-230x-14-49] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
186 Gray WN, Graef DM, Schuman SS, Janicke DM, Hommel KA. Parenting stress in pediatric IBD: relations with child psychopathology, family functioning, and disease severity. J Dev Behav Pediatr 2013;34:237-44. [PMID: 23669870 DOI: 10.1097/DBP.0b013e318290568a] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
187 Koido S, Ohkusa T, Kajiura T, Shinozaki J, Suzuki M, Saito K, Takakura K, Tsukinaga S, Odahara S, Yukawa T. Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy. PLoS One. 2014;9:e86702. [PMID: 24489770 DOI: 10.1371/journal.pone.0086702] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
188 Olendzki BC, Silverstein TD, Persuitte GM, Ma Y, Baldwin KR, Cave D. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutr J. 2014;13:5. [PMID: 24428901 DOI: 10.1186/1475-2891-13-5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 108] [Article Influence: 12.8] [Reference Citation Analysis]
189 Inokuchi T, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol 2014; 20(2): 509-517 [PMID: 24574719 DOI: 10.3748/wjg.v20.i2.509] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
190 Cox JH, Hussell S, Søndergaard H, Roepstorff K, Bui JV, Deer JR, Zhang J, Li ZG, Lamberth K, Kvist PH, Padkjær S, Haase C, Zahn S, Odegard VH. Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function. PLoS One 2013;8:e82944. [PMID: 24376610 DOI: 10.1371/journal.pone.0082944] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
191 Koido S, Ohkusa T, Saito H, Yokoyama T, Shibuya T, Sakamoto N, Uchiyama K, Arakawa H, Osada T, Nagahara A, Watanabe S, Tajiri H. Seasonal variations in the onset of ulcerative colitis in Japan. World J Gastroenterol 2013; 19(47): 9063-9068 [PMID: 24379632 DOI: 10.3748/wjg.v19.i47.9063] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
192 Lee J. Use of antioxidants to prevent cyclosporine a toxicity. Toxicol Res 2010;26:163-70. [PMID: 24278520 DOI: 10.5487/TR.2010.26.3.163] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
193 Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
194 Sood A, Midha V, Sharma S, Sood N, Bansal M, Thara A, Khanna P. Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience. Indian J Gastroenterol 2014;33:31-4. [PMID: 23999683 DOI: 10.1007/s12664-013-0372-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
195 Azzarito V, Long K, Murphy NS, Wilson AJ. Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem 2013;5:161-73. [PMID: 23422557 DOI: 10.1038/nchem.1568] [Cited by in Crossref: 527] [Cited by in F6Publishing: 495] [Article Influence: 58.6] [Reference Citation Analysis]
196 Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
197 Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
198 Odes S. Where are we going with ulcerative colitis management? Expert Opin Emerg Drugs 2013;18:1-4. [PMID: 23368663 DOI: 10.1517/14728214.2013.767330] [Reference Citation Analysis]
199 Schmidt KJ, Fellermann K, Büning J. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. Aliment Pharmacol Ther 2013;37:502. [PMID: 23336691 DOI: 10.1111/apt.12214] [Reference Citation Analysis]
200 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
201 Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, Yurci A, Güven K, Yücesoy M. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 2013;27:72-6. [PMID: 23292894 DOI: 10.1002/jcla.21564] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 12.6] [Reference Citation Analysis]
202 Katsuno T, Saito K, Yokosuka O. Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis? Authors' reply. Aliment Pharmacol Ther 2013;37:161. [PMID: 23205481 DOI: 10.1111/apt.12139] [Reference Citation Analysis]
203 Chaudhary MA, Fan T. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biol Ther. 2013;3:45-60. [PMID: 24392304 DOI: 10.1007/s13554-012-0007-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
204 Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol 2013;10:8-9. [PMID: 23229328 DOI: 10.1038/nrgastro.2012.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
205 Ramakrishna BS, Makharia GK, Abraham P, Ghoshal UC, Jayanthi V, Agarwal BK, Ahuja V, Bhasin DK, Bhatia SJ, Choudhuri G. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian J Gastroenterol. 2012;31:307-323. [PMID: 23096266 DOI: 10.1007/s12664-012-0259-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
206 Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6:427-433. [PMID: 23170145 DOI: 10.5009/gnl.2012.6.4.427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
207 Beck PL, Wallace JL. Cytokines in inflammatory bowel disease. Mediat of Inflammat. 1997;6:95-103. [PMID: 18472842 DOI: 10.1080/09629359791785] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
208 Madretsma GS, Dijk AP, Tak CJ, Wilson JH, Zijlstra FJ. Inhibition of the production of mediators of inflammation by corticosteroids is a glucocorticoid receptor-mediated process. Mediators Inflamm 1996;5:100-3. [PMID: 18475705 DOI: 10.1155/S0962935196000166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
209 Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, Conesa-Zamora P. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol. 2013;69:431-438. [PMID: 22960943 DOI: 10.1007/s00228-012-1389-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 5.4] [Reference Citation Analysis]
210 Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947-957. [PMID: 22954378 DOI: 10.1517/14740338.2012.720970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
211 Cowan ML, Fichera A. Ileal Pouch–Anal Anastomosis—A Surgical Perspective. Seminars in Colon and Rectal Surgery 2012;23:110-6. [DOI: 10.1053/j.scrs.2012.04.004] [Reference Citation Analysis]
212 Bennis M, Tiret E. Chirurgische Behandlung der Colitis ulcerosa. coloproctology 2012;34:273-9. [DOI: 10.1007/s00053-012-0275-7] [Reference Citation Analysis]
213 Dayan B, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. World J Gastroenterol 2012; 18(29): 3833-3838 [PMID: 22876035 DOI: 10.3748/wjg.v18.i29.3833] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
214 Baik SH, Kim WH. A comprehensive review of inflammatory bowel disease focusing on surgical management. J Korean Soc Coloproctol 2012;28:121-31. [PMID: 22816055 DOI: 10.3393/jksc.2012.28.3.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
215 Takaishi H, Kanai T, Nakazawa A, Sugata F, Nikai A, Yoshizawa S, Hamamoto Y, Funakoshi S, Yajima T, Iwao Y. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype. J Gastroenterol. 2012;47:969-977. [PMID: 22644337 DOI: 10.1007/s00535-012-0566-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
216 Nemoto H, Kataoka K, Ishikawa H, Ikata K, Arimochi H, Iwasaki T, Ohnishi Y, Kuwahara T, Yasutomo K. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci. 2012;57:2955-2964. [PMID: 22623042 DOI: 10.1007/s10620-012-2236-y] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 8.8] [Reference Citation Analysis]
217 Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18(16): 1861-1870 [PMID: 22563165 DOI: 10.3748/wjg.v18.i16.1861] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
218 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
219 Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010;23:274-84. [PMID: 22131898 DOI: 10.1055/s-0030-1268254] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
220 Bamba S, Andoh A, Imaeda H, Ban H, Kobori A, Mochizuki Y, Shioya M, Nishimura T, Inatomi O, Sasaki M, Saitoh Y, Tsujikawa T, Fujiyama Y. Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med 2012;4:99-104. [PMID: 23060930 DOI: 10.3892/etm.2012.545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
221 Kayahan H, Sari I, Cullu N, Yuksel F, Demir S, Akarsu M, Goktay Y, Unsal B, Akpinar H. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci. 2012;57:2137-2143. [PMID: 22466100 DOI: 10.1007/s10620-012-2148-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
222 Dulger AC, Begenik H, Demirtas L, Esen R, Emre H. A Flare of Ulcerative Colitis Accompanied With Cerebral Sinus Venous Thrombosis And Bilateral Thalamic Infarctus: A Case Report. Gastroenterology Res 2012;5:67-70. [PMID: 27785183 DOI: 10.4021/gr403w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
223 Fu YT, Chatur N, Cheong-Lee C, Salh B. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci. 2012;57:2144-2148. [PMID: 22451117 DOI: 10.1007/s10620-012-2130-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
224 Chaparro M. [Advances in the management of ulcerative colitis presented at Digestive Disease Week 2011]. Gastroenterol Hepatol 2011;34 Suppl 2:52-9. [PMID: 22330157 DOI: 10.1016/S0210-5705(11)70021-8] [Reference Citation Analysis]
225 Hisamatsu T, Okamoto S, Hashimoto M, Muramatsu T, Andou A, Uo M, Kitazume MT, Matsuoka K, Yajima T, Inoue N. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One. 2012;7:e31131. [PMID: 22303484 DOI: 10.1371/journal.pone.0031131] [Cited by in Crossref: 108] [Cited by in F6Publishing: 121] [Article Influence: 10.8] [Reference Citation Analysis]
226 Büning J, Fellermann K. [Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare]. Internist (Berl) 2011;52:833-40. [PMID: 21660632 DOI: 10.1007/s00108-010-2797-9] [Reference Citation Analysis]
227 Cho JH, Lee CK, Kim HJ, Shim JJ, Jang JY, Dong SH, Kim BH, Chang YW. Efficacy of Infliximab Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: Single Center Experience. Intest Res 2012;10:152. [DOI: 10.5217/ir.2012.10.2.152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
228 Mishra J, Waters CM, Kumar N. Molecular mechanism of interleukin-2-induced mucosal homeostasis. Am J Physiol Cell Physiol 2012;302:C735-47. [PMID: 22116305 DOI: 10.1152/ajpcell.00316.2011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
229 Gray WN, Denson LA, Baldassano RN, Hommel KA. Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. J Pediatr Psychol. 2012;37:282-291. [PMID: 22080456 DOI: 10.1093/jpepsy/jsr092] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
230 Herzer M, Denson LA, Baldassano RN, Hommel KA. Patient and parent psychosocial factors associated with health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;52:295-9. [PMID: 21297508 DOI: 10.1097/MPG.0b013e3181f5714e] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
231 Bennis M, Tiret E. Surgical management of ulcerative colitis. Langenbecks Arch Surg. 2012;397:11-17. [PMID: 21922296 DOI: 10.1007/s00423-011-0848-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
232 Odell S, Sander E, Denson LA, Baldassano RN, Hommel KA. The contributions of child behavioral functioning and parent distress to family functioning in pediatric inflammatory bowel disease. J Clin Psychol Med Settings 2011;18:39-45. [PMID: 21359503 DOI: 10.1007/s10880-011-9228-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
233 Longo SA, Moore RC, Canzoneri BJ, Robichaux A. Gastrointestinal Conditions during Pregnancy. Clin Colon Rectal Surg 2010;23:80-9. [PMID: 21629625 DOI: 10.1055/s-0030-1254294] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
234 Hanauer SB, Wald A. Acute and chronic megacolon. Curr Treat Options Gastroenterol 2007;10:237-47. [PMID: 17547862 DOI: 10.1007/s11938-007-0017-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
235 Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol. 2009;2:99-108. [PMID: 21180538 DOI: 10.1177/1756283x09102329] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
236 Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology. 2011;140:1838-1846. [PMID: 21530750 DOI: 10.1053/j.gastro.2011.02.014] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
237 Hommel KA, Denson LA, Baldassano RN. Oral medication adherence and disease severity in pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:250-254. [PMID: 21304318 DOI: 10.1097/meg.0b013e328344019c] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
238 Leković Z, Radlović N, Brdar R, Vuletić B, Janić N, Ristić D, Stojsić Z, Radlović V, Simić D, Nikolić D. Clinical characteristics of idiopathic ulcerative colitis in children. Srp Arh Celok Lek 2011;139:170-3. [PMID: 21618864 DOI: 10.2298/sarh1104170l] [Reference Citation Analysis]
239 Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis. ISRN Gastroenterol. 2011;2011:194324. [PMID: 21991497 DOI: 10.5402/2011/194324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
240 Herzer M, Denson LA, Baldassano RN, Hommel KA. Family functioning and health-related quality of life in adolescents with pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23:95-100. [PMID: 21079514 DOI: 10.1097/MEG.0b013e3283417abb] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
241 Ishikawa D, Ando T, Watanabe O, Ishiguro K, Maeda O, Miyake N, Nakamura M, Miyahara R, Ohmiya N, Hirooka Y, El-Omar EM, Goto H. Images of colonic real-time tissue sonoelastography correlate with those of colonoscopy and may predict response to therapy in patients with ulcerative colitis. BMC Gastroenterol 2011;11:29. [PMID: 21453450 DOI: 10.1186/1471-230X-11-29] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
242 Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011; 17(5): 547-556 [PMID: 21350703 DOI: 10.3748/wjg.v17.i5.547] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
243 Guilfoyle SM, Denson LA, Baldassano RN, Hommel KA. Paediatric parenting stress in inflammatory bowel disease: application of the Pediatric Inventory for Parents. Child Care Health Dev 2012;38:273-9. [PMID: 21299591 DOI: 10.1111/j.1365-2214.2010.01200.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
244 Souza MMD, Barbosa DA, Espinosa MM, Belasco AGS. Qualidade de vida de pacientes portadores de doença inflamatória intestinal. Acta paul enferm 2011;24:479-84. [DOI: 10.1590/s0103-21002011000400006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
245 Moussata D, Goetz M, Gloeckner A, Kerner M, Campbell B, Hoffman A, Biesterfeld S, Flourie B, Saurin JC, Galle PR, Neurath MF, Watson AJ, Kiesslich R. Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut 2011;60:26-33. [PMID: 20980342 DOI: 10.1136/gut.2010.213264] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 7.5] [Reference Citation Analysis]
246 Lago P. Ulcerative colitis: history of a successful treatment. BioDrugs 2010;24 Suppl 1:34-6. [PMID: 21175235 DOI: 10.2165/11586230-000000000-00000] [Reference Citation Analysis]
247 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
248 Gray WN, Denson LA, Baldassano RN, Hommel KA. Disease activity, behavioral dysfunction, and health-related quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1581-1586. [PMID: 21674715 DOI: 10.1002/ibd.21520] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
249 Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, Koch A. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180-8. [PMID: 20955707 DOI: 10.1053/j.gastro.2010.10.014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
250 Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010; 1(5): 87-93 [PMID: 21577301 DOI: 10.4292/wjgpt.v1.i5.87] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
251 Hommel KA, Odell S, Sander E, Baldassano RN, Barg FK. Treatment adherence in paediatric inflammatory bowel disease: perceptions from adolescent patients and their families. Health Soc Care Community 2011;19:80-8. [PMID: 21143544 DOI: 10.1111/j.1365-2524.2010.00951.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
252 Kunz JH, Hommel KA, Greenley RN. Health-related quality of life of youth with inflammatory bowel disease: a comparison with published data using the PedsQL 4.0 generic core scales. Inflamm Bowel Dis 2010;16:939-46. [PMID: 19998462 DOI: 10.1002/ibd.21128] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
253 Kobayashi T, Naganuma M, Okamoto S, Hisamatsu T, Inoue N, Ichikawa H, Takayama T, Saito R, Sujino T, Ogata H. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010;45:1129-1137. [PMID: 20614157 DOI: 10.1007/s00535-010-0273-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
254 Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17:7-19. [PMID: 20011280 DOI: 10.1055/s-2004-823066] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
255 Bryan S, Andronis L, Hyde C, Connock M, Fry-smith A, Wang D. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technol Assess 2010;14:9-15. [DOI: 10.3310/hta14suppl1-02] [Reference Citation Analysis]
256 Sasaki M, Johtatsu T, Kurihara M, Iwakawa H, Tanaka T, Bamba S, Tsujikawa T, Fujiyama Y, Andoh A. Energy expenditure in Japanese patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr 2010;47:32-6. [PMID: 20664728 DOI: 10.3164/jcbn.10-07] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
257 Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol 2009;21:558-64. [PMID: 19194304 DOI: 10.1097/MEG.0b013e328326cacb] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
258 Rocha R, Santana GO, Almeida N, Lyra AC. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr 2009;101:676-9. [PMID: 18631418 DOI: 10.1017/S0007114508032224] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
259 Hommel KA, Baldassano RN. Brief report: Barriers to treatment adherence in pediatric inflammatory bowel disease. J Pediatr Psychol 2010;35:1005-10. [PMID: 20026567 DOI: 10.1093/jpepsy/jsp126] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
260 Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
261 Takeda S, Sato T, Katsuno T, Nakagawa T, Noguchi Y, Yokosuka O, Saito Y. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci. 2010;55:1886-1895. [PMID: 19908144 DOI: 10.1007/s10620-009-0974-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
262 Ingerski LM, Baldassano RN, Denson LA, Hommel KA. Barriers to oral medication adherence for adolescents with inflammatory bowel disease. J Pediatr Psychol. 2010;35:683-691. [PMID: 19776229 DOI: 10.1093/jpepsy/jsp085] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
263 Cronin KC, Colleran GC, Smyth A, Houlihan DD, O'Gorman TA. Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report. Cases J 2009;2:6715. [PMID: 19918537 DOI: 10.4076/1757-1626-2-6715] [Reference Citation Analysis]
264 Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, Dupas JL, Savoye G, Baldé M, Marti R, Lerebours E, Cortot A, Salomez JL, Turck D, Colombel JF. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009;104:2080-8. [PMID: 19436273 DOI: 10.1038/ajg.2009.177] [Cited by in Crossref: 209] [Cited by in F6Publishing: 187] [Article Influence: 16.1] [Reference Citation Analysis]
265 Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009;15:589-93. [PMID: 18985746 DOI: 10.1002/ibd.20798] [Cited by in Crossref: 88] [Cited by in F6Publishing: 95] [Article Influence: 6.8] [Reference Citation Analysis]
266 Long MD, Plevy SE. Poorly responsive ulcerative colitis in the hospital. Clin Gastroenterol Hepatol 2009;7:635-40. [PMID: 19306946 DOI: 10.1016/j.cgh.2009.03.012] [Reference Citation Analysis]
267 Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Lian J, Lefèbvre C, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, Mcgovern D, Palmieri O, Achkar JP, Xavier RJ, Daly MJ, Duerr RH, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009;58:799-804. [PMID: 19201773 DOI: 10.1136/gut.2008.166918] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 7.6] [Reference Citation Analysis]
268 Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto T. Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver 2009;3:41-7. [PMID: 20479900 DOI: 10.5009/gnl.2009.3.1.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
269 Kamikozuru K, Fukunaga K, Hirota S, Hida N, Ohda Y, Yoshida K, Yokoyama Y, Tozawa K, Kawa K, Iimuro M, Nagase K, Saniabadi AR, Nakamura S, Miwa H, Matsumoto T. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol. 2009;156:320-327. [PMID: 19292766 DOI: 10.1111/j.1365-2249.2009.03904.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
270 Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:585-90. [PMID: 19006615 DOI: 10.1007/s11894-008-0106-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
271 Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43. [PMID: 19174792 DOI: 10.1038/ajg.2008.118] [Cited by in Crossref: 341] [Cited by in F6Publishing: 276] [Article Influence: 26.2] [Reference Citation Analysis]
272 Ravishankar PG, Velayos FS. Forecasting cyclosporine success or failure. Inflamm Bowel Dis 2009;15:152-3. [PMID: 18465806 DOI: 10.1002/ibd.20503] [Reference Citation Analysis]
273 Imaoka A, Umesaki Y. Rationale for Using of Bifidobacterium Probiotic Strains-Fermented Milk Against Colitis Based on Animal Experiments and Clinical Trials. Probiotics Antimicrob Proteins 2009;1:8-14. [PMID: 26783127 DOI: 10.1007/s12602-008-9001-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
274 Huguet Malavés JM, Ruiz Sánchez L, Ferrer Arranz L, Medina Chuliá E. [Infliximab as rescue therapy after cyclosporin in an acute ulcerative colitis flare]. Gastroenterol Hepatol 2008;31:626. [PMID: 19091261 DOI: 10.1157/13128311] [Reference Citation Analysis]
275 Yen EF, Kane SV, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008;103:3094-105. [PMID: 18775007 DOI: 10.1111/j.1572-0241.2008.02130.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
276 Ohama T, Hori M, Fujisawa M, Kiyosue M, Hashimoto M, Ikenoue Y, Jinno Y, Miwa H, Matsumoto T, Murata T. Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients. J Gastroenterol. 2008;43:858-865. [PMID: 19012039 DOI: 10.1007/s00535-008-2241-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
277 Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157-1167. [PMID: 18547130 DOI: 10.2165/00003495-200868090-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
278 Kohn A. Is there a role for infliximab in severe ulcerative colitis?: The European experience. Inflammatory Bowel Diseases 2008;14:S234-5. [DOI: 10.1097/00054725-200810001-00109] [Reference Citation Analysis]
279 Assche GV, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol 2008; 14(36): 5508-5511 [PMID: 18810767 DOI: 10.3748/wjg.14.5508] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
280 Umehara Y, Kudo M, Kawasaki M. Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. World J Gastroenterol 2008; 14(34): 5316-5321 [PMID: 18785285 DOI: 10.3748/wjg.14.5316] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
281 Spiegel BM, Ho W, Esrailian E, Targan S, Higgins PD, Siegel CA, Dubinsky M, Melmed GY. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol. 2009;7:168-174, 174.e1. [PMID: 18952199 DOI: 10.1016/j.cgh.2008.08.029] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
282 van den Broek FJ, Fockens P, van Eeden S, Reitsma JB, Hardwick JC, Stokkers PC, Dekker E. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 2008;57:1083-9. [PMID: 18367559 DOI: 10.1136/gut.2007.144097] [Cited by in Crossref: 192] [Cited by in F6Publishing: 167] [Article Influence: 13.7] [Reference Citation Analysis]
283 Rizzello F, Campieri M, Tambasco R, Straforini G, Brugnera R, Poggioli G, Gionchetti P. Medical treatment and management of severe ulcerative colitis. Dig Liver Dis 2008;40 Suppl 2:S280-4. [PMID: 18599001 DOI: 10.1016/S1590-8658(08)60538-1] [Reference Citation Analysis]
284 Greenstein RJ, Su L, Juste RA, Brown ST. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. PLoS One. 2008;3:e2496. [PMID: 18575598 DOI: 10.1371/journal.pone.0002496] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
285 Huguet Malavés JM, Ruiz Sánchez L, Durá Ayet AB, Rodríguez García I, Latorre Sánchez M, Ferrer Arranz L, Tuset Ruiz JA, Tomé Toyosato A, Medina Chuliá E. [Effectiveness of maintenance azathioprine therapy without oral cyclosporine after severe attacks of ulcerative colitis refractory to endovenous steroids]. Gastroenterol Hepatol 2008;31:280-4. [PMID: 18448056 DOI: 10.1157/13119879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
286 Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
287 Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:937-43. [PMID: 18177449 DOI: 10.1111/j.1572-0241.2007.01718.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 5.5] [Reference Citation Analysis]
288 Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008;33:867-74. [PMID: 18337262 DOI: 10.1093/jpepsy/jsn022] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 6.4] [Reference Citation Analysis]
289 Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, Daniel F, Beaugerie L, Cosnes J. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637-42. [PMID: 18047542 DOI: 10.1111/j.1572-0241.2007.01653.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
290 Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008;43:51-56. [PMID: 18297436 DOI: 10.1007/s00535-007-2129-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
291 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 148] [Cited by in F6Publishing: 141] [Article Influence: 10.6] [Reference Citation Analysis]
292 Matsumoto T, Fukunaga K, Kamikozuru K, Tozawa K, Yokoyama Y, Kusaka T, Onishi K, Miwa H, Nakamura S. Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease. Transfus Med Hemother. 2008;35:18-23. [PMID: 21547106 DOI: 10.1159/000111763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
293 Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzén H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007;102:2513-9. [PMID: 17680849 DOI: 10.1111/j.1572-0241.2007.01435.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
294 Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. [PMID: 17934839 DOI: 10.1007/s10620-007-9954-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
295 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
296 Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 5.3] [Reference Citation Analysis]
297 Feagan BG. Medical Management of Ulcerative Colitis in 2006: What's on the Horizon? Am J Gastroenterology 2007;102:S7-S13. [DOI: 10.1111/j.1572-0241.2007.01292.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
298 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
299 Blomberg B, Järnerot G. Clinical evaluation and management of acute severe colitis. Inflamm Bowel Dis 2000;6:214-27. [DOI: 10.1002/ibd.3780060309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
300 Cohen MB, Seidman E, Winter H, Colletti RB, Kirschner B, Balistreri WF, Grand RJ. Controversies in pediatric inflammatory bowel disease. Inflamm Bowel Dis 1998;4:203-27. [DOI: 10.1002/ibd.3780040306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
301 Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57. [DOI: 10.1002/ibd.3780060110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
302 Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007;52:2063-8. [PMID: 17436102 DOI: 10.1007/s10620-006-9691-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
303 Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci. 2007;52:2725-2731. [PMID: 17404876 DOI: 10.1007/s10620-006-9560-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
304 Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13. [PMID: 17389040 DOI: 10.1186/1471-230x-7-13] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
305 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
306 Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J Autism Dev Disord. 2006;36:1053-1064. [PMID: 16845577 DOI: 10.1007/s10803-006-0141-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
307 Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol. 2006;41:524-532. [PMID: 16868799 DOI: 10.1007/s00535-006-1789-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
308 Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007;42:16-25. [PMID: 17322989 DOI: 10.1007/s00535-006-1995-7] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 11.0] [Reference Citation Analysis]
309 Minami M, Ohta M, Ohkura T, Ando T, Ohmiya N, Niwa Y, Goto H. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007; 13(5): 754-760 [PMID: 17278199 DOI: 10.3748/wjg.v13.i5.754] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
310 Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, Okamoto S, Morohoshi Y, Izumiya M, Ichikawa H, Sato T, Inoue N, Ogata H, Hibi T. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007;102:331-7. [PMID: 17156136 DOI: 10.1111/j.1572-0241.2006.00989.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 143] [Article Influence: 10.0] [Reference Citation Analysis]
311 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
312 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 4.7] [Reference Citation Analysis]
313 Ikeuchi H, Yamamura T, Kusunoki M, Nakano H, Uchino M, Nakamura M, Noda M, Yanagi H, Matsumoto T. Leukocyte removal therapy for ulcerative colitis does not affect postoperative complications. J Gastroenterol 2006;41:848-54. [PMID: 17048048 DOI: 10.1007/s00535-006-1875-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
314 Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
315 Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J 2006;82:270-3. [PMID: 16597815 DOI: 10.1136/pgmj.2005.043901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
316 Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-74. [PMID: 16603634 DOI: 10.1136/gut.2005.089854] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 6.4] [Reference Citation Analysis]
317 Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, Okamoto S, Inoue N, Takaishi H, Ogata H. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol. 2006;41:318-324. [PMID: 16741610 DOI: 10.1007/s00535-005-1768-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
318 Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol 2006;126:365-76. [PMID: 16880149 DOI: 10.1309/UAXMW3428PGN9HJ3] [Cited by in Crossref: 84] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
319 Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62. [PMID: 16484504 DOI: 10.1136/gut.2005.081794] [Cited by in Crossref: 307] [Cited by in F6Publishing: 273] [Article Influence: 19.2] [Reference Citation Analysis]
320 Herrlinger KR, Fellermann K, Stange EF. Tacrolimus--finally! Gut 2006;55:1224-5. [PMID: 16905691 DOI: 10.1136/gut.2006.093302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
321 Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006;55:437-41. [PMID: 16531519 DOI: 10.1136/gut.2005.078055] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
322 Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis. 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
323 Sawada K, Takahashi R, Saniabadi AR, Ohdo M, Shimoyama T. Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous. World J Gastroenterol 2006; 12(10): 1621-1625 [PMID: 16570358 DOI: 10.3748/wjg.v12.i10.1621] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
324 Zwiers A, Bouma G. Recent advances in the etiology and treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2006;2:245-56. [PMID: 20477075 DOI: 10.1586/1744666X.2.2.245] [Reference Citation Analysis]
325 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
326 Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
327 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 365] [Cited by in F6Publishing: 338] [Article Influence: 22.8] [Reference Citation Analysis]
328 Hanauer SB. Reply. Gastroenterology 2006;130:286-7. [DOI: 10.1053/j.gastro.2005.11.038] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
329 Kountouras J, Zavos C, Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004;8:317-28. [PMID: 15491507 DOI: 10.1111/j.1582-4934.2004.tb00321.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
330 Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, Herfarth H, Schlitt HJ, Geissler EK. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis 2006;21:747-53. [PMID: 16228179 DOI: 10.1007/s00384-005-0793-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
331 Inoue T, Hirata I, Egashira Y, Ishida K, Kawakami K, Morita E, Murano N, Yasumoto S, Murano M, Toshina K, Nishikawa T, Hamamoto N, Nakagawa K, Katsu KI. Refractory ulcerative colitis accompanied with cytomegalovirus colitis and multiple liver abscesses: A case report. World J Gastroenterol 2005; 11(33): 5241-5244 [PMID: 16127763 DOI: 10.3748/wjg.v11.i33.5241] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
332 Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, Fukushima T, Uede T, Hibi T. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005;54:1254-62. [PMID: 16099792 DOI: 10.1136/gut.2004.048298] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 5.5] [Reference Citation Analysis]
333 Gironella M, Iovanna JL, Sans M, Gil F, Peñalva M, Closa D, Miquel R, Piqué JM, Panés J. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 2005;54:1244-53. [PMID: 15870231 DOI: 10.1136/gut.2004.056309] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 4.6] [Reference Citation Analysis]
334 Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu H, Masuda J, Handa K, Harada K, Nishida H, Toyonaga A, Sata M. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005;141:130-40. [PMID: 15958079 DOI: 10.1111/j.1365-2249.2005.02825.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
335 Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-9. [PMID: 15929771 DOI: 10.1111/j.1572-0241.2005.41089.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 6.0] [Reference Citation Analysis]
336 Waters V, Sokol S, Reddy B, Soong G, Chun J, Prince A. The effect of cyclosporin A on airway cell proinflammatory signaling and pneumonia. Am J Respir Cell Mol Biol 2005;33:138-44. [PMID: 15879161 DOI: 10.1165/rcmb.2005-0005OC] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
337 Nikolaus S, Schreiber S, Fölsch UR. [Pharmacologic therapy for inflammatory bowel diseases: hopes, disappointments]. Internist (Berl) 2005;46:586-91. [PMID: 15806413 DOI: 10.1007/s00108-005-1386-9] [Reference Citation Analysis]
338 Auernhammer CJ, Zitzmann K, Schnitzler F, Seiderer J, Lohse P, Vlotides G, Engelhardt D, Sackmann M, Göke B, Ochsenkühn T. Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease. World J Gastroenterol 2005; 11(8): 1196-1199 [PMID: 15754404 DOI: 10.3748/wjg.v11.i8.1196] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
339 Leong RW, Lawrance IC, Ching JY, Cheung CM, Fung SS, Ho JN, Philpott J, Wallace AR, Sung JJ. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci. 2004;49:1672-1676. [PMID: 15573925 DOI: 10.1023/b:ddas.0000043384.26092.f4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
340 Ross AS, Cohen RD. Medical therapy for ulcerative colitis: The state of the art and beyond. Curr Gastroenterol Rep 2004;6:488-95. [DOI: 10.1007/s11894-004-0071-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
341 Kaser A, Ludwiczek O, Holzmann S, Moschen AR, Weiss G, Enrich B, Graziadei I, Dunzendorfer S, Wiedermann CJ, Mürzl E. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24:74-85. [PMID: 14997037 DOI: 10.1023/b:joci.0000018066.46279.6b] [Cited by in Crossref: 134] [Cited by in F6Publishing: 137] [Article Influence: 7.4] [Reference Citation Analysis]
342 Kaser A, Ludwiczek O, Holzmann S, Moschen AR, Weiss G, Enrich B, Graziadei I, Dunzendorfer S, Wiedermann CJ, Mürzl E. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24:74-85. [PMID: 14997037 DOI: 10.1023/b: joci.0000018066.46279.6b] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
343 Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.04337253/suppl_5/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.043372] [Cited by in Crossref: 730] [Cited by in F6Publishing: 687] [Article Influence: 40.6] [Reference Citation Analysis]
345 McColl E, Han SW, Barton JR, Welfare MR. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004;13:805-11. [PMID: 15129890 DOI: 10.1023/B:QURE.0000021701.28467.57] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
346 Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85. [PMID: 15233681 DOI: 10.1111/j.1572-0241.2004.40036.x] [Cited by in Crossref: 440] [Cited by in F6Publishing: 396] [Article Influence: 24.4] [Reference Citation Analysis]
347 Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004;49:469-474. [PMID: 15139501 DOI: 10.1023/b:ddas.0000020506.84248.f9] [Cited by in Crossref: 170] [Cited by in F6Publishing: 172] [Article Influence: 9.4] [Reference Citation Analysis]
348 Kühbacher T, Schreiber S, Fölsch UR. Ulcerative colitis: conservative management and long-term effects. Langenbecks Arch Surg. 2004;389:350-353. [PMID: 15133672 DOI: 10.1007/s00423-004-0477-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
349 Holtmann MH, Galle PR. Current concept of pathophysiological understanding and natural course of ulcerative colitis. Langenbecks Arch Surg. 2004;389:341-349. [PMID: 14760536 DOI: 10.1007/s00423-003-0448-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
350 Kamm MA. Antagonist: Early surgical intervention in ulcerative colitis. Gut 2004;53:308-9. [PMID: 14724169 DOI: 10.1136/gut.2003.001727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
351 Siveke JT, Folwaczny C. Medical approaches and future options in chronic active ulcerative colitis. Int J Colorectal Dis 2004;19:297-307. [PMID: 14727131 DOI: 10.1007/s00384-003-0569-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
352 Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003;98:2363-71. [PMID: 14638335 DOI: 10.1111/j.1572-0241.2003.07696.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 99] [Article Influence: 7.7] [Reference Citation Analysis]
353 Vlachonikolis IG, Pallis AG, Mouzas IA. Improved validation of the Inflammatory Bowel Disease Questionnaire and development of a short form in Greek patients. Am J Gastroenterol 2003;98:1802-12. [PMID: 12907336 DOI: 10.1111/j.1572-0241.2003.07518.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
354 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 234] [Cited by in F6Publishing: 231] [Article Influence: 12.3] [Reference Citation Analysis]
355 Tomomasa T, Kobayashi A, Kaneko H, Mika S, Maisawa S, Chino Y, Syou H, Yoden A, Fujino J, Tanikawa M, Yamashita T, Kimura S, Kanoh M, Sawada K, Morikawa A. Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 2003;48:750-754. [PMID: 12741466 DOI: 10.1023/a:1022892927121] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
356 Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, Asakura H, Nakano H, Takahama K, Fujiyama Y. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002;37 Suppl 14:67-72. [PMID: 12572869 DOI: 10.1007/bf03326417] [Cited by in Crossref: 125] [Cited by in F6Publishing: 103] [Article Influence: 6.6] [Reference Citation Analysis]
357 Loftus CG, Loftus EV Jr, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut 2003;52:172-3. [PMID: 12524395 DOI: 10.1136/gut.52.2.172] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
358 Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76. [PMID: 12591057 DOI: 10.1111/j.1572-0241.2003.07239.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
359 García-Planella E, Domènech E, Cabré E, Bernal MI, Gassull MA. [Intravenous cyclosporine A in the treatment of refractory Crohn's disease]. Med Clin (Barc) 2002;119:610-2. [PMID: 12433336 DOI: 10.1016/s0025-7753(02)73514-8] [Reference Citation Analysis]
360 Ardizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Saf. 2002;25:561-582. [PMID: 12113642 DOI: 10.2165/00002018-200225080-00003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
361 Banić M, Anić B, Brkić T, Ljubicić N, Plesko S, Dohoczky C, Erceg D, Petrovecki M, Stipancić I, Rotkvić I. Effect of cyclosporine in a murine model of experimental colitis. Dig Dis Sci. 2002;47:1362-1368. [PMID: 12064814 DOI: 10.1023/A:1015339018181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
362 Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97:803-23. [PMID: 12003413 DOI: 10.1111/j.1572-0241.2002.05596.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 86] [Article Influence: 5.0] [Reference Citation Analysis]
363 Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723-751. [PMID: 11707060 DOI: 10.2165/00003088-200140100-00003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 4.8] [Reference Citation Analysis]
364 Mcleod RS. The Management of Fulminant Colitis: . Inflammatory Bowel Diseases 2002;8:138-9. [DOI: 10.1097/00054725-200203000-00011] [Reference Citation Analysis]
365 Dvorchik I, Subotin M, Demetris AJ, Fung JJ, Starzl TE, Wieand S, Abu-Elmagd KM. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002;35:380-4. [PMID: 11826412 DOI: 10.1053/jhep.2002.30695] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
366 Endo Y, Tsuzuki H, Fujino M, Tabata T, Oka H, Shimizu T, Hanasawa K, Tani T. Off-line leukapheresis using leukofiltration for active ulcerative colitis: a case report. Ther Apher 2001;5:480-3. [PMID: 11800085 DOI: 10.1046/j.1526-0968.2001.00385.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
367 Pallis AG, Vlachonikolis IG, Mouzas IA. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterol 2002;2:1. [PMID: 11866863 DOI: 10.1186/1471-230x-2-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 2.5] [Reference Citation Analysis]
368 Rosencrantz R, Moon A, Raynes H, Spivak W. Cyclosporine-Induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am J Gastroenterol 2001;96:2778-82. [PMID: 11569712 DOI: 10.1111/j.1572-0241.2001.04111.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
369 Legnani PE, Kornbluth A. Immunomodulator Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2001;4:199-205. [PMID: 11469977 DOI: 10.1007/s11938-001-0032-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
370 Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6. [PMID: 11302961 DOI: 10.1136/gut.48.5.642] [Cited by in Crossref: 250] [Cited by in F6Publishing: 223] [Article Influence: 11.9] [Reference Citation Analysis]
371 Cottone M, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, Orlando A, Rosselli M, Rizzo A, Pagliaro L. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001;96:773-5. [PMID: 11280549 DOI: 10.1111/j.1572-0241.2001.03620.x] [Cited by in Crossref: 205] [Cited by in F6Publishing: 200] [Article Influence: 9.8] [Reference Citation Analysis]
372 Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenterol 2000; 6(4): 483-489 [PMID: 11819634 DOI: 10.3748/wjg.v6.i4.483] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
373 Yeung MM, Melgar S, Baranov V, Oberg A, Danielsson A, Hammarström S, Hammarström ML. Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-gammadelta expression. Gut 2000;47:215-27. [PMID: 10896913 DOI: 10.1136/gut.47.2.215] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 4.4] [Reference Citation Analysis]
374 Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-8. [PMID: 10950049 DOI: 10.1111/j.1572-0241.2000.02186.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 3.0] [Reference Citation Analysis]
375 Rampton DS. Management of difficult inflammatory bowel disease: where are we now? World J Gastroenterol 2000; 6(3): 315-323 [PMID: 11819588 DOI: 10.3748/wjg.v6.i3.315] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
376 Wong CK, Yacyshyn BR. Fulminant Ulcerative Colitis. Curr Treat Options Gastroenterol 2000;3:217-26. [PMID: 11097739 DOI: 10.1007/s11938-000-0025-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
377 Ghosh S, Shand A, Ferguson A. Ulcerative colitis. BMJ 2000;320:1119-23. [PMID: 10775225 DOI: 10.1136/bmj.320.7242.1119] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
378 Phipatanakul W, Winkelstein JA, Lake AM. Cyclosporine Treatment of Intractable Colitis in Chronic Granulomatous Disease. Pediatr Asthma Allergy Immunol 2009;14:125-7. [PMID: 22328803 DOI: 10.1089/pai.2000.14.125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
379 Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 1999;21:311-323. [PMID: 10514022 DOI: 10.2165/00002018-199921040-00006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
380 Hurd LB, Lichtenstein GR. Therapeutic potential of infliximab in inflammatory bowel disease. Gastroenterol Nurs 1999;22:199-208. [PMID: 10776108 DOI: 10.1097/00001610-199909000-00003] [Reference Citation Analysis]
381 Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45:382-8. [PMID: 10446106 DOI: 10.1136/gut.45.3.382] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 3.7] [Reference Citation Analysis]
382 Rampton DS, Phil D. New treatments for inflammatory bowel disease. World J Gastroenterol 1998; 4(5): 369-376 [PMID: 11819324 DOI: 10.3748/wjg.v4.i5.369] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
383 Modigliani R. Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Inflamm Bowel Dis 1998;4:244-7; discussion 253-4. [PMID: 9741030 DOI: 10.1097/00054725-199808000-00008] [Reference Citation Analysis]
384 Meijssen MA. Cyclosporine and inflammatory bowel disease: buying time. Mediators Inflamm 1998;7:145-7. [PMID: 9705599 DOI: 10.1080/09629359891054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
385 Ardizzone S, Bianchi Porro G. A practical guide to the management of distal ulcerative colitis. Drugs. 1998;55:519-542. [PMID: 9561342 DOI: 10.2165/00003495-199855040-00004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
386 Dʼhaens G, Suenaert P, Westhovens R, Rutgeerts P. Severe Knee Pain as the Single Symptom of CMV Infection in Acute Ulcerative Colitis Treated with Cyclosporine: . Inflammatory Bowel Diseases 1998;4:27-8. [DOI: 10.1097/00054725-199802000-00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
387 Akerkar GA, Peppercorn MA. Inflammatory bowel disease in the elderly. Practical treatment guidelines. Drugs Aging. 1997;10:199-208. [PMID: 9108893 DOI: 10.2165/00002512-199710030-00004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
388 Carbonnel F, Boruchowicz A, Duclos B, Soulé JC, Lerebours E, Lémann M, Belaïche J, Colombel JF, Cosnes J, Gendre JP. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci. 1996;41:2471-2476. [PMID: 9011460 DOI: 10.1007/bf02100145] [Cited by in Crossref: 96] [Cited by in F6Publishing: 81] [Article Influence: 3.8] [Reference Citation Analysis]
389 Miner PB. Opinion: Placebos Are an Important Aspect of Studies of Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1997;3:22-4. [DOI: 10.1097/00054725-199703000-00005] [Reference Citation Analysis]
390 Daum F. The Correct Sequence of Treatment for Pediatric Inflammatory Bowel Disease (IBD)-Nutrition or Steroids and/or Immunosuppression? Steroids and/or Immunosuppression! Nutrition Is to Grow, Steroids and/or Immunosuppression Are to Heal: . Inflammatory Bowel Diseases 1997;3:54-7. [DOI: 10.1097/00054725-199703000-00009] [Reference Citation Analysis]
391 Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10. [PMID: 8984031 DOI: 10.1136/gut.38.6.905] [Cited by in Crossref: 488] [Cited by in F6Publishing: 429] [Article Influence: 18.8] [Reference Citation Analysis]
392 Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. Combined Use of Cyclosporine and Azathioprine or 6-Mercaptopurine in Pediatric Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology & Nutrition 1996;22:296-302. [DOI: 10.1097/00005176-199604000-00012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 2.9] [Reference Citation Analysis]
393 Eliakim R, Rachmilewitz D. Inflammatory Bowel Disease: The Asthma of the Intestine?: . Inflammatory Bowel Diseases 1996;2:122-32. [DOI: 10.1097/00054725-199606000-00010] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
394 Vermeire S, Rutgeerts P. Cyclosporine Monotherapy Is Effective in the Treatment of Severe Ulcerative Colitis: . Inflammatory Bowel Diseases 1996;2:253-4. [DOI: 10.1097/00054725-199612000-00004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
395 Steinhart HA. Randomized Controlled Trials in Inflammatory Bowel Diseases: The Case for the Positive Control: . Inflammatory Bowel Diseases 1996;2:260-4. [DOI: 10.1097/00054725-199612000-00006] [Reference Citation Analysis]
396 Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995;38:1241-5. [PMID: 7497833 DOI: 10.1007/BF02049146] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 2.0] [Reference Citation Analysis]